Welcome to our dedicated page for Dalrada Financl SEC filings (Ticker: DFCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dalrada Technology Group, Inc. filings document the public-company record of the issuer formerly known as Dalrada Financial Corporation, including periodic-report timing, material events, governance changes, and financing-related obligations. Recent Form 8-K disclosures cover officer changes, shareholder communications, and material definitive agreements involving subsidiary Genefic, including credit, security, account-purchase, standby letter of credit, and guaranty arrangements.
The filing record also reflects the company's operating focus across renewable energy and heat pumps, atmospheric water generators, semiconductor deposition solutions, and health care services. Form 12b-25 notices address delayed periodic reports and audit-review timing, while amended 8-K filings update previously reported direct financial obligation disclosures.
Dalrada Technology Group, Inc. submitted a Form 12b-25 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026. The company says additional time is needed to compile and analyze information, complete financial statements and disclosures, and allow review by its independent registered public accounting firm. Dalrada expects to file the Form 10-Q as soon as practicable and no later than the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25.
Dalrada Technology Group reported continued losses and severe balance sheet weakness for the quarter ended December 31, 2025. Total revenue was $3.26 million, roughly flat versus the prior year’s $3.11 million, while six‑month revenue fell to $7.36 million from $9.15 million. Gross profit improved to $1.12 million in the quarter, but selling, general and administrative expenses of $4.70 million kept operations unprofitable, leading to a quarterly operating loss of $3.57 million and a six‑month net loss of $10.49 million.
The company’s financial position is strained. It ended the period with only $70,074 of cash and cash equivalents, total assets of $17.59 million, and total liabilities of $34.49 million, resulting in a stockholders’ deficit of $16.90 million. Management discloses negative working capital of $15.34 million and states there is “substantial doubt” about Dalrada’s ability to continue as a going concern without new financing and improved subsidiary performance.
Dalrada relies heavily on related‑party financing, with $8.58 million in related‑party payables and $4.64 million in related‑party notes payable, and has layered on multiple high‑cost loans and revenue purchase agreements. Operating cash outflows of $3.26 million in the first half of fiscal 2026 were covered only by $3.00 million of net cash from financing activities.
Dalrada Technology Group, Inc. filed a notification that it will be late submitting its quarterly report on Form 10-Q for the period ended December 31, 2025. The company states the filing delay is because it is in the final review process with its auditors and indicates the report will be filed within the standard grace period allowed. Dalrada also reports that all other required periodic reports over the past 12 months have been filed and that it does not anticipate any significant change in results of operations compared with the same period last year.
Dalrada Technology Group, through its subsidiary Genefic Inc., amended a prior report to clarify that new financing agreements create up to $25,000,000 in aggregate commitments, not $20,000,000 as first disclosed. The package combines up to $20,000,000 of standby letters of credit and related guarantees with a linked $5,000,000 revolving accounts receivable facility supporting Genefic’s healthcare operations.
The facilities run from December 31, 2025 to December 31, 2030 and are secured by first-priority liens on substantially all assets of Genefic and the parent company, plus a pledge of 100% of equity in all subsidiaries. Chairman and CEO Brian Bonar has provided an unlimited personal guaranty that is joint and several with the company’s obligations, and the board highlights resulting conflicts of interest between his personal exposure and his duties to shareholders. Upfront consideration includes $140,000 in cash, a $165,000 promissory note, and a pre-funded warrant valued at $225,000.
Dalrada Technology Group, through its wholly owned subsidiary Genefic Inc., entered into a financing structure providing up to $20,000,000 in guarantees and related credit support with IBS-affiliated funds. A related receivables-based revolving facility may provide up to $5,000,000 in funding for Genefic’s healthcare operations.
The arrangements are secured by first-priority liens on substantially all assets of Genefic and a first-priority security interest in substantially all assets of Dalrada, plus a pledge of 100% of the equity in all Dalrada subsidiaries. CEO Brian Bonar also provided an unlimited personal guaranty of Genefic’s obligations, which the Board identified as creating multiple potential conflicts of interest. Dalrada did not receive separate consideration for its upstream guarantee beyond benefits to Genefic.
Dalrada Technology Group, Inc. filed a current report to share that its Chief Executive Officer and Chairman, Brian Bonar, issued an open letter to shareholders dated January 20, 2026. The letter reviews the company’s 2025 performance, discusses operational progress in its core markets of renewable energy and heat pumps, atmospheric water generators, and semiconductor deposition solutions, and highlights recent partnerships, installations, and restructuring efforts. It also outlines Dalrada’s strategic focus and outlook for 2026 and beyond. The letter is included as Exhibit 99.1 and is furnished, rather than filed, under the securities laws.
Dalrada Financial Corporation (DFCO) reported fiscal Q1 2026 results for the quarter ended September 30, 2025. Total revenue was $4,098,786, down from $6,030,655 a year ago, with product sales weaker and services making up most of the quarter. Gross profit was $560,178 and the company posted a net loss of $6,063,068, similar to the prior year’s loss.
Operating expenses were $5,879,442. Cash used in operating activities was $4,216,845, offset by $4,521,215 of financing cash inflows, largely from related party notes. As of September 30, 2025, assets totaled $17,984,117 and liabilities were $30,582,753, resulting in a stockholders’ deficit of $12,598,636. Management disclosed negative working capital of $11,660,541 and “substantial doubt” about the company’s ability to continue as a going concern, citing reliance on collections from healthcare payers, heat pump sales, and subsidiary projects.
As of November 14, 2025, common shares outstanding were 120,157,113. Related party notes payable increased to $3,723,405. Deferred revenue reached $1,910,269, and contingent consideration remained $211,289.
Dalrada Technology Group, Inc. (f/k/a Dalrada Financial Corporation) reported that Chief Financial Officer Kyle McCollum resigned, effective immediately on October 31, 2025.
The company stated the resignation was not due to any disagreement regarding accounting practices, financial statements, or disclosures. Dalrada is identifying and appointing a successor and will provide updates in subsequent filings.
Dalrada Financial Corporation (DFCO) reports consolidated results showing revenue of $20.3 million for the year ended June 30, 2025 and a net loss before taxes of $(24.66) million, with net loss per common share to Dalrada stockholders of $(0.23) compared with $(0.31) in the prior year. The company recorded a goodwill impairment of approximately $2.7 million and disclosed a going concern qualification: negative operating cash flows raise substantial doubt about its ability to continue absent new equity or debt financing and improved cash collection from insurance payers, product sales and subsidiary operations.
At June 30, 2025 total assets include goodwill of $1.53 million and intangible assets of $3.11 million; total current liabilities include $15.74 million. Common shares outstanding were 120,157,113 as of September 29, 2025. The company completed multiple acquisitions (Grand Entrances, Genefic/IVS) and financed operations through related-party convertible preferred issuances and numerous notes payable; related-party debt conversions to Series I Preferred Stock and large warrant programs were noted. Lease and debt maturities and significant deferred tax assets are disclosed.